Low expression of Toll-like receptors in peripheral blood mononuclear cells of pediatric patients with acute lymphoblastic leukemia.
Cancer is the second most common cause of death among children aged 1-14 years. Leukemia accounts for one-third of all childhood cancers, 78% of which is acute lymphoblastic leukemia (ALL). The development of cancer has been associated with malignant cells that express low levels of immunogenic molecules, which facilitates their escape from the antineoplastic immune response. It is thought that it may be possible to rescue the antineoplastic immune response through the activation of recognition receptors, such as Toll-like receptors (TLRs), which activate the innate immune system. TLRs are type I membrane glycoproteins expressed mainly in immune system cells such as monocytes, neutrophils, macrophages, dendritic cells, T, B and natural killer cells. The aim of the present study was to evaluate the expression of TLR1, TLR3, TLR4, TLR7 and TLR9 in peripheral blood mononuclear cells (PBMCs) in patients with ALL and prior to any treatment. PBMCs were obtained from 50 pediatric patients diagnosed with ALL and from 20 children attending the ophthalmology and orthopedics services. The mean fluorescence intensity was obtained by analysis of immunofluorescence. We found lower expression levels of TLR1, TLR3, TLR4, TLR7 and TLR9 in PBMCs from patients with ALL compared with those from control patients. We also observed that the PBMCs from patients with Pre-B and B ALL had lower TLR4 expression than controls and patients with Pro-B, Pre-B, B and T ALL had lower TLR7 expression than controls. The present study is the first to demonstrate reduced expression of TLRs in PBMCs from pediatric patients with ALL. This finding is of great relevance and may partly explain the reduction in the antineoplastic immune response in patients with ALL.
Immunology and Proteomic Research Laboratory, Children's Hospital of Mexico Federico Gómez, Mexico City, Mexico.
María
M
Sánchez-Cuaxospa
Laboratory of Developmental Biology, Children's Hospital of Mexico Federico Gómez, Mexico City, Mexico.
Alejandra
A
Contreras-Ramos
Immunology and Proteomic Research Laboratory, Children's Hospital of Mexico Federico Gómez, Mexico City, Mexico.
Erandi
E
Pérez-Figueroa
Department of Hematology and Oncology, Children's Hospital of Mexico Federico Gómez, Mexico City, Mexico.
Aurora
A
Medina-Sansón
Oncology Service, Children's Hospital Moctezuma, Mexico City, Mexico.
Elva
E
Jiménez-Hernández
Oncology Service, Children's Hospital Moctezuma, Mexico City, Mexico.
José R
JR
Torres-Nava
Institute of Biomedical Sciences, National Autonomous University of Mexico, Mexico City, Mexico.
Emilio
E
Rojas-Castillo
Immunology and Proteomic Research Laboratory, Children's Hospital of Mexico Federico Gómez, Mexico City, Mexico.
Carmen
C
Maldonado-Bernal
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D003713:Dendritic Cells / Q000473:pathology; D005260:Female; D015973:Gene Expression Regulation, Leukemic / Q000235:genetics; D006801:Humans; D007223:Infant; D007694:Killer Cells, Natural / Q000473:pathology; D007963:Leukocytes, Mononuclear / Q000473:pathology; D008264:Macrophages / Q000473:pathology; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood* / Q000473:pathology; D051195:Toll-Like Receptor 2 / Q000097:blood*; D051196:Toll-Like Receptor 3 / Q000097:blood*; D051197:Toll-Like Receptor 4 / Q000097:blood*; D051199:Toll-Like Receptor 7 / Q000097:blood*; D051217:Toll-Like Receptor 9 / Q000097:blood*
C495344:TLR3 protein, human; D051195:Toll-Like Receptor 2; D051196:Toll-Like Receptor 3; D051197:Toll-Like Receptor 4; D051199:Toll-Like Receptor 7; D051217:Toll-Like Receptor 9